Dechra Pharmaceuticals Share Price

Equities

DPH

GB0009633180

Market Closed - London S.E. 01:00:00 16/01/2024 pm IST 5-day change 1st Jan Change
3,866 GBX -.--% Intraday chart for Dechra Pharmaceuticals -.--% +0.21%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 682M 866M 72.1B Sales 2023 762M 968M 80.53B Capitalization 4.2B 5.33B 444B
Net income 2022 58M 73.71M 6.13B Net income 2023 -27M -34.31M -2.86B EV / Sales 2022 5.8 x
Net Debt 2022 208M 265M 22.02B Net Debt 2023 430M 547M 45.48B EV / Sales 2023 6.08 x
P/E ratio 2022
64.8 x
P/E ratio 2023
-150 x
Employees -
Yield 2022
1.3%
Yield 2023
0.34%
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
6 months+1.26%
Current year+0.21%
More quotes
Current year
3 853.34
Extreme 3853.3425
3 868.00
1 year
3 060.00
Extreme 3060
4 145.84
3 years
2 473.32
Extreme 2473.323
5 525.00
5 years
2 030.00
Extreme 2030
5 525.00
10 years
677.00
Extreme 677
5 525.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 13/97/13
Director of Finance/CFO 44 01/10/01
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 63 13/97/13
Chairman - 01/20/01
Director/Board Member - 01/22/01
More insiders
Dechra Pharmaceuticals PLC specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows: - companion animal products (74.6%); - food producing animal products (11.5%); - equine health products (7.3%); - animal feeds (5.1%); - other (1.5%): products manufactured by third parties. Net sales are distributed geographically as follows: the United Kingdom (8.5%), Germany (9.2%), Europe (31.2%), the United States (37.9%) and other (13.2%).
Sector
-
More about the company
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW